Comparative Pharmacology
Head-to-head clinical analysis: NITRO IV versus NITRO BID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITRO IV versus NITRO BID.
NITRO IV vs NITRO-BID
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Nitroglycerin is a vasodilator that primarily acts by relaxing vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase to increase cGMP, leading to venodilation and, at higher doses, arterial dilation. This reduces preload and afterload, decreasing myocardial oxygen demand.
Nitroglycerin is a nitrate that relaxes vascular smooth muscle by conversion to nitric oxide (NO), which activates guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP) levels, leading to vasodilation. Primarily dilates veins, reducing preload and myocardial oxygen demand; also dilates coronary arteries.
Acute angina pectorisProphylaxis of angina (before exercise or stress)Congestive heart failure (acute)Controlled hypotension during surgeryHypertensive emergencies (off-label)Pulmonary edema (off-label)
Prophylaxis of angina pectorisTreatment of acute angina attacksOff-label: acute myocardial infarction (limited use), heart failure with pulmonary edema (if not hypotensive)
Initial infusion rate 5 mcg/min via continuous IV infusion, titrate by 5 mcg/min every 3-5 minutes until response; usual maintenance dose 10-20 mcg/min; maximum 200 mcg/min.
Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses. Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours, then removed for 10-12 hours.
None Documented
None Documented
1-4 minutes (rapidly cleared from blood); terminal half-life ~2-3 minutes due to rapid biotransformation in RBCs and vascular tissue.
Terminal half-life of nitroglycerin is 1-4 minutes; clinical effects are short-lived due to rapid redistribution and metabolism.
Nitroglycerin is extensively metabolized in the liver by glutathione S-transferases and, to a lesser extent, by arterial walls. It undergoes denitration to form 1,2- and 1,3-glyceryl dinitrate, which have weaker vasodilatory activity.
Rapidly metabolized via hepatic glutathione-organic nitrate reductase to dinitrates and mononitrates; also metabolized in erythrocytes and vascular tissue.
Renal (minimal, <1% unchanged) and hepatic metabolism; metabolites excreted renally.
Renal: <1% unchanged; extensive metabolism followed by renal excretion of metabolites, with minor biliary/fecal elimination (<5%).
60% bound to albumin.
Approximately 60% bound to plasma proteins (mainly albumin).
3-4 L/kg (high, due to extensive tissue uptake, especially vascular smooth muscle).
Vd approximately 3.3 L/kg, indicating extensive distribution into tissues beyond plasma volume.
IV: 100% (not administered via other routes due to extensive first-pass metabolism).
Sublingual: ~40% (high first-pass hepatic metabolism); Transdermal: ~72% (bypasses first-pass); Oral: <10% due to extensive hepatic metabolism.
No dose adjustment required for GFR ≥30 mL/min; for GFR <30 mL/min, consider dose reduction due to risk of methemoglobinemia and cyanide toxicity, monitor closely.
No specific adjustment required; nitroglycerin is minimally renally excreted.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use or use with extreme caution, reduce dose by 75%.
Child-Pugh A: no adjustment. Child-Pugh B: consider dose reduction (25-50% of normal dose). Child-Pugh C: avoid or use with extreme caution; reduce dose by 50% or more.
0.25-0.5 mcg/kg/min IV continuous infusion, titrate by 0.5-1 mcg/kg/min every 3-5 minutes; maximum 5 mcg/kg/min for children.
Not routinely recommended; limited data. Intravenous: start at 0.25-0.5 mcg/kg/min, titrate by 0.5-1 mcg/kg/min every 3-5 min to effect; max 5 mcg/kg/min.
Initiate at lower end of dosing range (5 mcg/min) due to increased sensitivity; titrate slowly with careful hemodynamic monitoring.
Start at lower end of dosing range due to increased sensitivity and risk of hypotension. Sublingual: 0.3 mg initial. Transdermal: 0.2 mg/hour initially.
Nitroglycerin is contraindicated in patients with severe anemia, increased intracranial pressure, or those using phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) due to risk of severe hypotension.
No FDA boxed warning specifically for NITRO-BID. However, nitroglycerin is contraindicated with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to severe hypotension.
["Hypotension and reflex tachycardia may occur; monitor blood pressure","May exacerbate angina from abrupt discontinuation (tolerance and rebound)","Caution in patients with hypovolemia, right ventricular infarction, or hypertrophic cardiomyopathy","Avoid in patients with constrictive pericarditis or pericardial tamponade","May cause methemoglobinemia, especially with high doses or prolonged use"]
May cause severe hypotension, especially with volume depletion; avoid in patients with hypertrophic cardiomyopathy; use caution in hepatic/renal impairment; tolerance develops with chronic use; may aggravate angina when discontinuing abruptly.
["Allergy to nitroglycerin or nitrates","Severe anemia","Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage)","Concomitant use of phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil)","Hypotension (systolic BP < 90 mmHg)","Right ventricular infarction","Constrictive pericarditis","Pericardial tamponade"]
Hypersensitivity to nitrates; concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil); severe anemia; increased intracranial pressure; circulatory failure or shock; right ventricular infarction; constrictive pericarditis; cardiac tamponade.
Data Pending Review
Data Pending Review
No specific food restrictions. Avoid alcohol as it may enhance vasodilation and hypotension.
Avoid alcohol as it may cause hypotension. No specific food interactions; maintain usual diet.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal harm at high doses. Second/third trimester: Potential risk of fetal bradycardia and hypotension; use only if clearly needed. Avoid near term due to risk of uterine relaxation and hemorrhage.
Pregnancy Category C. Animal studies have shown fetal harm (bradycardia, reduced birth weight). Inadequate human data for first trimester; avoid unless benefit outweighs risk. Second and third trimesters: associated with maternal hypotension and fetal bradycardia; use only if clearly needed.
Unknown excretion in human milk. M/P ratio not established. Short half-life suggests minimal exposure; however, use with caution and consider risk of infant hypotension.
Excreted in breast milk in small amounts; M/P ratio approximately 0.5. Although risk to infant appears low, caution is advised. Monitor infant for hypotension, methemoglobinemia (rare).
No standard dose adjustment in pregnancy. Consider higher initial doses due to increased volume of distribution and clearance, but titrate to effect due to potential for heightened sensitivity.
No formal dose adjustment studies in pregnancy. Pharmacokinetic changes (increased plasma volume, altered protein binding) may require upward titration. Start at lowest effective dose and titrate based on maternal hemodynamic response (BP, HR). Avoid maternal hypotension (systolic <100 mmHg).
Category C
Category C
Use non-PVC infusion sets to minimize drug adsorption. Monitor for hypotension, especially with concurrent PDE-5 inhibitor use. Tolerance can develop with prolonged infusion; use lowest effective dose. Do not abruptly discontinue after prolonged use to avoid rebound ischemia. Avoid in patients with right ventricular infarction or severe aortic stenosis.
NITRO-BID (nitroglycerin ointment) is used for prophylaxis of angina pectoris. Apply to hairless skin, preferably chest or upper arm. Rotate sites to avoid irritation. Do not rub in; spread thin layer. Tolerance develops with continuous use; remove at bedtime to provide nitrate-free interval. Avoid in patients with severe hypotension, hypertrophic obstructive cardiomyopathy, or concurrent use of phosphodiesterase-5 inhibitors (e.g., sildenafil).
Report any severe headaches, dizziness, or fainting during infusion.Avoid taking erectile dysfunction medications like sildenafil or tadalafil while on this treatment.Notify your healthcare provider if you have a history of low blood pressure or recent heart attack.The medication will be given by a healthcare professional and vital signs will be monitored closely.Do not stop the infusion suddenly without medical advice.
Apply the prescribed amount to skin, do not rub in.Wash hands after application.Rotate application sites to prevent skin irritation.Remove the ointment at bedtime to prevent tolerance.Store at room temperature away from heat and open flame.Seek emergency care if chest pain persists after use.